| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V102611 | 2-Methyl-3-phenylquinoxaline | 10130-23-1 | 2-Methyl-3-phenylquinoxaline (Compound 38) is a potent inhibitor of platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) and has limited inhibitory activity against PDGFR kinase in intact cells (IC50 greater than 100 μM). |
|
V2880 | AC710 | 1351522-04-7 | AC710 is a potent, orally bioactive, and selectiveinhibitor of PDGFR (platelet-derived growth factor receptor) family kinase withKdvalues of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively. |
|
V2093 | AC710 Mesylate | 1351522-05-8 | AC710 mesylate, the mesylate salt of AC710, is a potent, orally bioactive, and selectiveinhibitor of PDGFR (platelet-derived growth factor receptor) family kinase withKdvalues of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively. |
|
V131266 | CDK2/FLT4/PDGFRA-IN-1 | CDK2/FLT4/PDGFRA-IN-1 is a potent CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA inhibitor with IC50 values of 1.672, 0.554 and 0.629 μM, respectively. | |
|
V88059 | cis-SU4312 | 90828-16-3 | cis-SU4312 ((Z)-SU4312) inhibits PDGFR and FLK-1 with IC50 of 19.4 and 0.8 μM, respectively. |
|
V0577 | CP-673451 | 343787-29-1 | CP-673451 (CP673451) is a novel, potent, selective and ATP-competitive inhibitor of PDGFR(α/β) with potential antitumor activity. |
|
V0575 | MK-2461 | 917879-39-1 | MK-2461 (MK2461) is a novel,potent, ATP-competitive, multi-targeted inhibitor for c-Met (WT/mutants) with potential antineoplastic activity. |
|
V142355 | PDGFRA-IN-1 | PDGFRA-IN-1 is a platelet-derived growth factor receptor A (PDGFRA) inhibitor with an IC50 of 1.25 μM. | |
|
V118823 | PDGFRalpha D842V Recombinant Human Active Protein Kinase | PDGFRα is a receptor tyrosine kinase that can stimulate cell survival, proliferation, and migration. | |
|
V144388 | RPR-101511 | 146535-06-0 | RPR-101511 is a 3-substituted quinoline derivative. |
|
V69297 | Toceranib-d8 (Toceranib d8) | 1795134-78-9 | Toceranib-d8 is the deuterated form of Toceranib. |
|
V0574 | Tyrphostin AG 1296 | 146535-11-7 | Tyrphostin AG 1296 (AG-1296) is a novel, potent, selective and ATP-competitive inhibitor of PDGFR with potential antitumor activity. |
|
V0573 | Imatinib (STI571; Gleevec; Glivec) | 152459-95-5 | Imatinib (formerly STI-571, trade name Gleevec and Glivec) is an orally bioavailable multi-targeted kinase inhibitor with potential anticancer activity. |
|
V0580 | Crenolanib (CP-868596; RO 002; ARO 002) | 670220-88-9 | Crenolanib (formerly also known as CP868596; RO-002; ARO-002), a benzimidazole compound, is an orally bioavailable and selective small molecule inhibitor of platelet-derived growth factor receptor (PDGFRα/β) with potential anticancer activity. |
|
V3698 | Toceranib | 356068-94-5 | Toceranib (formerly known as PHA-291639, or SU-11654) is an inhibitor of receptor tyrosine kinase (RTK) with anticancer activities. |
|
V3284 | Ripretinib (DCC-2618) | 1442472-39-0 | Ripretinib (DCC-2618; DCC2618; Qinlock) is a potent, orally bioactive, and spectrum-selective pan KIT and PDGFRA inhibitor approved in 2020 as an anticancer medication for treating gastrointestinal stromalcancers. |
|
V0579 | Amuvatinib (MP470; HPK56) | 850879-09-3 | Amuvatinib (MP-470; HPK-56) is a novel, potent, orally bioavailableand multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with potential antineoplastic activity. |
|
V0576 | Masitinib (AB1010) | 790299-79-5 | Masitinib (formerly also known as AB1010) is a novel, potent, orally bioavailable, selective and multi-targeted inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, it shows weak inhibition to ABL and c-Fms. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
